董丽娜,刘国平,刘艾芹,赵 晔,于 磊.高通量血液透析联合左卡尼汀对老年维持性血液透析患者免疫功能、氧化应激和微炎症状态的影响[J].现代生物医学进展英文版,2021,(22):4335-4339. |
高通量血液透析联合左卡尼汀对老年维持性血液透析患者免疫功能、氧化应激和微炎症状态的影响 |
Effects of High Flux Hemodialysis Combined with Levocarnitine on Immune Function, Oxidative Stress and Microinflammation State in Elderly Maintenance Hemodialysis Patients |
Received:March 27, 2021 Revised:April 23, 2021 |
DOI:10.13241/j.cnki.pmb.2021.22.028 |
中文关键词: 高通量血液透析 左卡尼汀 老年 维持性血液透析 免疫功能 氧化应激 微炎症状态 |
英文关键词: High flux hemodialysis Levocarnitine Elderly Maintenance hemodialysis Immune function Oxidative stress Microinflammation state |
基金项目:内蒙古自治区自然科学基金项目(2018MS08008) |
|
Hits: 665 |
Download times: 368 |
中文摘要: |
摘要 目的:观察高通量血液透析(HFHD)联合左卡尼汀在老年维持性血液透析(MHD)患者中的应用效果。方法:选择我院2020年1月~2021年2月间接收的100例老年MHD患者。采用随机数字表法将患者分为对照组(50例,接受HFHD治疗)和研究组(50例,接受HFHD联合左卡尼汀治疗),均治疗3个月。观察两组免疫功能、氧化应激、微炎症状态、其他血生化指标和治疗安全性。结果:与对照组相比,研究组治疗3个月后CD3+、CD4+、CD4+/CD8+更高,CD8+更低(P<0.05)。与对照组相比,研究组治疗3个月后血清白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)水平更低(P<0.05)。与对照组相比,研究组治疗3个月后血清超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)水平更高,丙二醛(MDA)水平更低(P<0.05)。与对照组相比,研究组治疗3个月后血红蛋白(Hb)、红细胞比容(Hct)、前白蛋白(PA)更高(P<0.05)。两组三酰甘油(TG)、总胆固醇(TC)组内治疗前、治疗3个月后以及组间对比统计学无意义(P>0.05)。与对照组相比,研究组不良反应总发生率更低(P<0.05)。结论:HFHD联合左卡尼汀可有效改善老年MHD患者免疫功能,改善机体营养状态,减轻氧化应激和微炎症状态,降低不良反应发生率,且对机体血脂代谢影响轻微。 |
英文摘要: |
ABSTRACT Objective: To observe the application effect of high flux hemodialysis (HFHD) combined with Levocarnitine in elderly maintenance hemodialysis (MHD) patients. Methods: 100 elderly MHD patients who were admitted to our hospital from January 2020 to February 2021 were selected. The patients were randomly divided into control group (50 cases, treated with HFHD) and study group (50 cases, treated with HFHD combined with Levocarnitine) by the random-number table method, all of which were treated for 3 months. The immune function, oxidative stress, microinflammation state, other blood biochemical indexes and treatment safety of the two groups were observed. Results: Compared with the control group, CD3+, CD4+, CD4+/CD8+ in the study group were higher, and CD8+ was lower (P<0.05). Compared with the control group, the serum levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and hypersensitive C-reactive protein(hs-CRP) in the study group at 3 months after treatment were lower(P<0.05). Compared with the control group, the levels of superoxide dismutase (SOD) and glutathione peroxidase(GSH-Px) in the study group at 3 months after treatment were higher, and the level of malondialdehyde (MDA) was lower (P<0.05). Compared with the control group, hemoglobin (Hb), hematocrit (Hct) and prealbumin (PA) in the study group at 3 months after treatment were higher(P<0.05). There were no significant differences in triglyceride (TG) and total cholesterol (TC) before treatment, 3 months after treatment and between the two groups (P>0.05). Compared with the control group, the total incidence of adverse reactions in the study group was lower(P<0.05). Conclusion: HFHD combined with Levocarnitine can effectively improve the immune function of elderly MHD patients, improve the nutritional status of the body, reduce oxidative stress and microinflammation state, reduce the incidence of adverse reactions, and have a slight impact on the metabolism of blood lipid in the body. |
View Full Text
View/Add Comment Download reader |
Close |
|
|
|